Trial Profile
Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy ResponSE in Hypogonadal Men (TRAVERSE) Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Testosterone (Primary)
- Indications Hypogonadism
- Focus Adverse reactions
- Acronyms TRAVERSE
- Sponsors AbbVie
- 18 Jan 2024 Results of a sub-trial assessing cardiovascular safety of testosterone treatment in middle-aged and older men with hypogonadism in a time-to-event analysis published in the New England Journal of Medicine
- 13 Dec 2022 Status changed from active, no longer recruiting to completed.
- 18 Feb 2022 Status changed from recruiting to active, no longer recruiting.